Drug Target Review

SEPTEMBER 4, 2023

10 Reported cAMP as the second messenger signalling molecule conserved from bacteria to humans and modulates several biological processes, including protein expression, gene transcription, and cell development and differentiation. link] Ojewale Kayode (2018). Doi.org/10.1038/s41592-019-0614-5 Ishita, G., Suruchi, A., Nilmar, S.

Drugs 111

Drugs RNA DNA Disease 111

The Pharma Data

JANUARY 16, 2021

Etta Biotech”), to set up a high titer transient protein expression platform for high quality protein production using JS Bio’s transient transfection media. JS Bio becomes the exclusive cell culture supplier for Etta Biotech’s transient transfection high titer protein expression platform.

Protein Expression 52

Protein Expression Protein Production Production Drug Development 52

Drug Target Review

JULY 5, 2023

This selectable marker enables the identification of cells which have taken up the GOIs and aids the initial selection of recombinant protein expressing cell lines. High-throughput screening of antibody-expressing CHO clones using an automated shaken deep-well system. 2018) 34(6): 1460-1471. Wang B, Albanetti T, et al.

Engineering 105

Engineering DNA Laboratories Production 105

The Pharma Data

SEPTEMBER 28, 2021

In addition, results from Part 1 of Study SRP-9001-102, an ongoing, randomised, double-blind, placebo-controlled clinical test evaluating the security , efficacy, and tolerability of one dose of SRP-9001 in 41 boys with DMD, showed that the study met its primary biological endpoint of change in micro-dystrophin protein expression from baseline.

Clinical Trials 52

Clinical Trials Protein Expression Therapies FDA 52

The Pharma Data

OCTOBER 26, 2020

Increased infiltrates, expression of immune related genes and higher PD-L1 protein expression were observed across all patients suggesting a remodeling of the tumor microenvironment consistent with a switch toward a “hot tumor” phenotype. Conclusions. .

Vaccine 40

Vaccine Trials Treatment Virus 40

The Pharma Data

JANUARY 13, 2021

Structure 3:1031-1039 (1995) 3 Waters J, Biocentury ; October 26, (2018) 4 NCT02273960; ClinicalTrials.gov ; “Study to Evaluate Safety and Efficacy in Adult Subjects With ITP (ITP)”; results posted April 1, 2019, updated July 29, 2019 and accessed Jan 11, 2021 5 Ferrant JL et al., 1 Lederman, S. International Immunol. (11):1583

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

The Pharma Data

APRIL 8, 2021

EVRYSDI was granted PRIME designation by the European Medicines Agency (EMA) in 2018 and Orphan Drug Designation by FDA and EMA in 2017 and 2019, respectively. Food and Drug Administration (FDA) approved EVRYSDI for the treatment of SMA in adults and children 2 months of age and older. About OCREVUS ® (ocrelizumab).

Clinical Trials 52

Clinical Trials Trials Disease Therapies 52